Hindcon Chemical (HINDCON)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Low debt/equity of 0.11 provides financial stability
• Promoter holding at 68.71% aligns management with minority shareholders
• Book value of ₹14.51 gives asset support with P/B of 1.50
• ROCE of 9.97% shows some capital efficiency despite recent profit collapse

Concerns

• Net profit down 76.47% with latest quarter net profit at ₹0 crore on ₹14 crore sales
• P/E of 35.11 is expensive for a business with declining earnings
• Piotroski F-Score of 3/9 signals weak financial health
• Sales declined 6.81% and dividend yield is zero

AI Analysis

At ₹21.81, Hindcon Chemical is a small-cap specialty chemical company with a market capitalization of ₹104 crore. My first rule is never lose money, and here the earnings record raises red flags. Trailing profits have collapsed by 76.47%, and the latest quarter shows net profit of essentially zero on sales of ₹14 crore. A P/E of 35.11 means I am paying 35 years of depressed earnings for a business that is not growing. Sales have declined 6.81%. This is not a franchise with pricing power; it looks like a commodity-like chemicals supplier struggling to maintain margins. The balance sheet is not frightening: debt/equity of 0.11 is low, and ROCE of 9.97% is acceptable but not spectacular. Book value of ₹14.51 gives some support, especially at P/B of 1.50, but I prefer a margin of safety below book, not above it. Promoter holding of 68.71% is good—my interests are aligned with owners—but high holding does not compensate for deteriorating fundamentals. The Piotroski F-Score of 3 out of 9 is poor, indicating weak operating efficiency, leverage, and asset quality signals. There is no dividend, so I receive no income while waiting. I would not call this a wonderful business at a fair price; it is a struggling business at an uncertain price. As Graham said, price is what you pay, value is what you get. The value here is not evident. I need evidence of margin stabilization, positive quarterly profit, and sales growth before considering entry. Until then, this is worth watching, not buying. A possible turnaround story, but only for patient investors who accept high risk and demand concrete proof.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer